Business Description
Taiko Pharmaceutical Co Ltd
ISIN : JP3442200006
Total Employee Number:
225Description
Taiko Pharmaceutical Co Ltd operates in three segments, namely Pharmaceutical, Infection Control, and Others. The majority of its revenue comes from Infection Control, which is into manufacturing and sales of sanitation control products, including Cleverin, Cleverin LED, and Cleverin Generator LISPASS. The pharmaceutical segment is into the manufacturing and sales of OTC medicines and designated quasi-drugs. Other business includes manufacturing and sales of wood vinegar-based products.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.34 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | 11.11 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 3.43 | |||||
Beneish M-Score | -2.46 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.3 | |||||
3-Year Book Growth Rate | -2.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 25.91 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 9.3 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 65.83 | |||||
9-Day RSI | 59.09 | |||||
14-Day RSI | 56.24 | |||||
3-1 Month Momentum % | -13.33 | |||||
6-1 Month Momentum % | -14.47 | |||||
12-1 Month Momentum % | -7.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.14 | |||||
Quick Ratio | 3.07 | |||||
Cash Ratio | 2.12 | |||||
Days Inventory | 658.83 | |||||
Days Sales Outstanding | 316.3 | |||||
Days Payable | 105.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.24 | |||||
Dividend Payout Ratio | 0.79 | |||||
Forward Dividend Yield % | 1.31 | |||||
5-Year Yield-on-Cost % | 1.24 | |||||
3-Year Average Share Buyback Ratio | -4.9 | |||||
Shareholder Yield % | 11.11 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 52.39 | |||||
Operating Margin % | -4.41 | |||||
Net Margin % | -4.96 | |||||
EBITDA Margin % | 2.16 | |||||
FCF Margin % | 23.42 | |||||
OCF Margin % | 37.37 | |||||
ROE % | -1.32 | |||||
ROA % | -0.91 | |||||
ROIC % | -1.4 | |||||
3-Year ROIIC % | -96.94 | |||||
ROC (Joel Greenblatt) % | -1.31 | |||||
ROCE % | -0.81 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 25.88 | |||||
Forward PE Ratio | 20.63 | |||||
PE Ratio without NRI | 66.36 | |||||
PS Ratio | 6.36 | |||||
PB Ratio | 1.68 | |||||
Price-to-Tangible-Book | 1.68 | |||||
Price-to-Free-Cash-Flow | 27.19 | |||||
Price-to-Operating-Cash-Flow | 17.03 | |||||
EV-to-EBIT | -135.38 | |||||
EV-to-EBITDA | 224.66 | |||||
EV-to-Revenue | 4.85 | |||||
EV-to-FCF | 20.01 | |||||
Price-to-GF-Value | 0.78 | |||||
Price-to-Projected-FCF | 2.26 | |||||
Price-to-Median-PS-Value | 1.79 | |||||
Price-to-Graham-Number | 2.23 | |||||
| Price-to-Net-Current-Asset-Value | 3.15 | |||||
| Price-to-Net-Cash | 17.99 | |||||
Earnings Yield (Greenblatt) % | -0.74 | |||||
FCF Yield % | 3.68 | |||||
Forward Rate of Return (Yacktman) % | 9.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Taiko Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil 円) | 2,178 | ||
| EPS (TTM) (円) | 10.66 | ||
| Beta | 0.1586 | ||
| 3-Year Sharpe Ratio | -0.13 | ||
| 3-Year Sortino Ratio | -0.2 | ||
| Volatility % | 28.58 | ||
| 14-Day RSI | 56.24 | ||
| 14-Day ATR (円) | 7.487958 | ||
| 20-Day SMA (円) | 271.35 | ||
| 12-1 Month Momentum % | -7.14 | ||
| 52-Week Range (円) | 246 - 335 | ||
| Shares Outstanding (Mil) | 50.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Taiko Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Taiko Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (円) | ||
|---|---|---|---|---|
| JPY 3.500000 Cash Dividend | 2026-12-29 | In 167 days | ||
| JPY 3.300000 Cash Dividend | 2025-12-29 | 294.00 (+0.00%) | ||
| 3:1 Stock Split | 2020-03-30 | 1,566.67 (-1.47%) | ||
| 3:1 Stock Split | 2009-07-28 | 770.00 (+2.67%) |
Show
Entries
Taiko Pharmaceutical Co Ltd Frequently Asked Questions
What is Taiko Pharmaceutical Co Ltd(TSE:4574)'s stock price today?
The current price of TSE:4574 is 円276.00. The 52 week high of TSE:4574 is 円335.00 and 52 week low is 円246.00.
When is next earnings date of Taiko Pharmaceutical Co Ltd(TSE:4574)?
The next earnings date of Taiko Pharmaceutical Co Ltd(TSE:4574) is .
Does Taiko Pharmaceutical Co Ltd(TSE:4574) pay dividends? If so, how much?
The Dividend Yield %  of Taiko Pharmaceutical Co Ltd(TSE:4574) is 1.24% (As of Today), Highest Dividend Payout Ratio of Taiko Pharmaceutical Co Ltd(TSE:4574) was 0.79. The lowest was 0.17. And the median was 0.21. The  Forward Dividend Yield % of Taiko Pharmaceutical Co Ltd(TSE:4574) is 1.31%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Taiko Pharmaceutical Co Ltd
No articles.